skyhin Sure boh, can justify cal ?
18/07/2020 6:52 PM

Of course there are various variables...like vaccine...macroeconomics n geopolitical to consider...if using only TA n FA...Probably within 1 year around...@8.80...!!!

xuxu @geary you are here, comfort is the MUST buy stock now.
14/07/2020 2:46 PM

Already bought last 4th week of June...

By 2021 January...TP...@6.80...!!!

Uncle KYY today.

Common sense will tell you that the Covid 19 pandemic will not be under control for at least another 6 months and the demand for gloves will continue to exceed supply.

You can avoid stress and worry if you just buy and hold for a few months. You don’t need a crystal ball or consult a fortune teller to tell you that the price for Supermax and other glove stocks will continue to go up higher and higher until the pandemic is under control.

President Trump banned 5G technology - Koon Yew Yin - Koon Yew Yin's Blog | I3investor

President Trump banned 5G technology - Koon Yew Yin
Author: Koon Yew Yin Publish date: Fri, 17 Jul 2020, 7:06 PM

US banned Huawei 5G technology. Huawei is the world's No. 1 telecom supplier and No. 2 phone manufacturer, but it's a pariah in countries like the US. Unfortunately, UK Prime Minister Boris Johnson, like an obedient dog wants to follow Trump to ban Huawei 5G networking equipment despite Huawei phone’s massive presence around the world. The US continues to pressure allies to block Huawei from their next-generation 5G wireless networks. In July, the UK opted to ban Huawei from its 5G infrastructure. The company's gear must be removed by 2027.

Donald Trump and Boris Johnson are so ignorant as they did not realise how much this new technology can help the people and the nations improve economically. Trump does not care as long as he can bash China to win more votes for his re-election in November. Unfortunately, most Americans also like to degrade China. All Americans and British people should open their eyes to read the following to know more about 5G technology.

What is 5G technology?

The new, faster standard will make possible what is frequently called the Internet of Things—the wireless connection of everyday items to allow data on them to be collected, analysed, and manipulated. These items could be anything, including mundane household appliances, farm equipment, watches and clocks, water mains, various robots, hospital devices, and even the computers and machines used by businesses and emergency services—all could be networked together, accessed, and monitored online. 5G will enable self-driving cars to communicate with each other and with traffic monitoring systems—potentially preventing accidents by reacting up to 200 times faster than human drivers. There is a world of possibilities and potential just waiting for the mind of man to explore it.

The big focus of 5G enthusiasm is about the vast increase in computing capabilities that will result from massive improvements in communication and extraordinary amounts of data transfer. Experts believe these developments may have the potential to generate a new Industrial Revolution, producing jobs and boosting national economies. Estimates suggest that in the next few years we could see literally millions of 5G base stations on Earth and 20,000 new 5G satellites in low Earth orbit, connected to 200 billion transmitting objects.

Wider rollout of 5G, however, is going to take significant investment and time before it reaches our neighbourhoods. Compared to 4G signals, which blanket the airwaves in all directions, 5G, at frequencies of 10 to 300GHz (gigahertz) and a one-millimetre wavelength, is unable to pass through buildings or trees and can even be disrupted by rainfall. To overcome these difficulties, 5G phased-array base antennas, transmitting multiple narrow, steerable, high-power signals, need to be positioned just 200 metres apart in a grid. The same antennas in all 5G devices, either stationary or moving, will seek to establish a continuous connection with the base antennas. Existing legislation will permit these signals to be at least ten times more powerful (up to 20 watts) than current 4G signals.

Ha...KYY can understand better than those pariah n lapdogs...!!!

NEW YORK CITY: The US is pinning its hopes on a COVID-19 coronavirus vaccine, but will a vaccine alone be enough to stop the pandemic and allow life to return to normal?

The answer depends on a how “good” the vaccine ends up being.

In a study published on Jul 15 in the American Journal of Preventive Medicine, my colleagues and I used a computer simulation of every person in the country to show how effective a vaccine would have to be and how many people would have to get vaccinated to end the pandemic.

We found that a coronavirus vaccine’s effectiveness may have to be higher than 70 per cent or even 80 per cent before Americans can safely stop relying on social distancing.

By comparison, the measles vaccine has an efficacy of 95 per cent to 98 per cent, and the flu vaccine is 20 per cent to 60 per cent.

IMPORTANCE OF AN EFFECTIVE VACCINE

Some political leaders have suggested that society will return to normal soon, especially if a vaccine becomes available by the end of the year or early in 2021. Some vaccines are currently in early-stage trials, but that timeline would still be very optimistic.

However, it is important to remember that a vaccine is like many other products: What matters is not just that the product is available but also how effective it is.

FILE PHOTO: Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe
Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe are seen in this illustration taken taken on Apr 10, 2020. (Photo: REUTERS/Dado Ruvic)
Different vaccines may offer different levels of protection. Scientists talk about this as the vaccine’s efficacy or effectiveness.

If 100 people who haven’t been exposed to the virus are given a vaccine that has an efficacy of 80 per cent, that means that on average 80 of them would not get infected.

The difference between efficacy and effectiveness is that the former applies when vaccination is given under controlled circumstances, like a clinical trial, and the latter is under “real-world” conditions. Typically, a vaccine’s effectiveness tends to be lower than its efficacy.

Since COVID-19 coronavirus vaccines are still under development, now is the time to set vaccine efficacy levels to aim for, as well as to manage expectations. Running computer simulations is really the only way to ethically do this.

Typically, in an epidemic or pandemic, as more people are exposed to the virus, the number of new infections per day steadily increases until it reaches a peak and begins to drop. Of course, how long this takes depends upon how the virus and the response to it may evolve over time.

To stop the pandemic, the number of new infections per day needs to drop to zero, or at least to a very low number, as quickly as possible.

If the COVID-19 pandemic were just beginning and the population infected was close to 0 per cent, the simulations show that vaccine efficacy would have to be at least 60 per cent to stop the coronavirus if the entire population was vaccinated.

Given the number of susceptible people who couldn’t be vaccinated because of age or health problems and the number who would refuse to be vaccinated, that’s probably impossible.

Trading of glove stocks is not for the uninitiated and faint-hearted

BURSA Malaysia is not a market for retailers. Some 30% of the index weighting is on glove stocks – namely Top Glove Corp Bhdand Hartalega Holdings Bhd.

On a single day, the price of the four glove stocks can gyrate anywhere between 20% and 30% and it is accompanied by huge volumes, which suggests that it is a playing ground for the funds as well as punters.

In a single day last week, Supermax Corp Bhd, which is among the top four glove companies, gyrated as much as RM5.30. It went as high as RM17.80 and as low as RM12.50, before closing the day at RM15.90.

A normal investor would probably have had a heart seizure. Anybody who had bought the stock at the peak with the view of selling on the same day would have lost his or her pants.

The story is the same for all the other glove stocks. The price gyration is scary, to say the least. The stocks are up in the morning before coming down late afternoon and picking up strongly by the end of the trading day.

Clearly, it is not the kind of market for retailers. It’s only for those who are really experienced in trading and understand the dynamics of jumping in and out without getting hurt.

Some research houses have tagged unprecedented valuations on glove stocks. It’s surprising that even the foreign houses have raised the price of the top-notch glove companies such as Top Glove and Hartalega to more than RM30. Credit Suisse’s target for Top Glove is RM37.

Glove stocks are trading at historical price earnings (PE) multiple of between 75 time and 170 times at current prices. Among the four glove manufacturers, the stock with the highest PE multiple is Supermax while Kossan Rubber Industries Bhdis at the lowest end at 75 times PE.

If the stocks hit the price targets as set out by the research houses, we are looking at Supermax possibly trading at almost 200 times PE and Top Glove at more than 120 times PE. The mind-boggling valuations are jaw-dropping but analysts seem to suggest that the stocks have the earnings potential.

Are analyst reports reliable?

The upgrade in price targets by research houses suggests that there is an impending earnings explosion of the companies in the second quarter. But what the research houses fail to stress is the sustainability of the earnings.

To the pessimist on glove stocks, they would say that analyst reports certainly are not a yardstick as they are just forecast numbers and not any indication to buy or sell the stock.

However, to be fair, some research houses had predicted Top Glove to be RM25 a month ago when it was barely touching RM15. Then, many had dismissed the price target as nonsensical. Now, RM25 seems to be a reasonable price for Top Glove for some.

Amidst the optimism surrounding glove stocks, it’s interesting to note that the major shareholders of Kossan have disposed of a little of their holdings in the market. The family of Tan Sri Lim Kuang Sia, who control Kossan and are known for not selling their shares even when prices were high, sold a few million shares in recent weeks.

The family still retains a substantial 47% in Kossan. Their move to take some money off the table is something that should not be dismissed. It’s a clear signal that glove stocks are looking over-valued.

The interest on glove stocks is so huge that it is said to be responsible for the crash of Bursa Malaysia’s trading system on Thursday. The crash came as there was heavy selling on glove stocks following news that the US authorities have stopped some shipments of Top Glove’s exports to that country.

The US market accounts for 25% of Top Glove’s exports and gives the highest average selling prices for the gloves. Hence, the impact is significant on Top Glove.

The announcement was out during the lunch break although news of the consignment being stopped seeped into the market in the morning. Top Glove resumed trading at 3.30pm. Shortly later, the system crashed.

Brokers feel that the crash came about because of the heavy sell order for glove stocks, which is not surprising considering the volume these stocks garner.

The run on the glove stocks is a reminder of the dotcom run in 1999 when semiconductor producers namely Malaysian Pacific IndustriesBhd and Unisem Bhd were the darlings of the stock market.

The stocks were on an uptrend for almost a year before the dotcom crash in 2000. The two stocks hit ballistic valuations that not many fund managers had envisaged. Until today, the two stocks are still considered the bell-weather for the tech sector.

But now there are many more players in the tech sector. They are diversified into several segments within the sector and Technology is an index within Bursa itself.

Similarly, the play on glove companies is now focused on the top four stocks. The others are enjoying the run on the sector. If demand for gloves continues, the sector will likely see more new names emerging on the stock market.

KUALA LUMPUR (July 18): Malaysia needs to have the capability to produce critical products, said Prime Minister Tan Sri Muhyiddin Yassin.

He said this covered the food and beverage sector, medical devices, medicines, petrochemicals, and personal protective equipment like gloves and face masks.

"When the country has this capability, we can reduce the outflow of the Malaysian currency and increase the export of local products,” he said when launching the national-level Mega Sales Programme and Buy Malaysian Products Campaign at Suria KLCC here today.

Therefore, the government is studying and review the existing policies to reduce dependence on imported products and give priority to building the capacity of local industries to produce made in Malaysia products, he added.

Covid19 Pandemic.

The first case was reported in China in early January and it took three months to reach 1 million cases. It has taken just four days to climb to 14 million cases from 13 million recorded on July 13.

Global coronavirus infections passed 14 million on Friday, according to a Reuterstally, marking the first time there has been a surge of 1 million cases in under 100 hours.

The first case was reported in China in early January and it took three months to reach 1 million cases. It has taken just four days to climb to 14 million cases from 13 million recorded on July 13.

The United States, with more than 3.6 million confirmed cases, is still seeing huge daily jumps in its first wave of COVID-19 infections. The United States reported a daily global record of more than 77,000 new infections on Thursday, while Sweden has reported 77,281 total cases since the pandemic began.

Despite the surging cases, a cultural divide is growing in the country over wearing masks to slow the spread of the virus, a precaution routinely taken in many other nations.

U.S. President Donald Trump and his followers have resisted a full-throated endorsement of masks and have been calling for a return to normal economic activity and reopening schools despite the surging cases.

Other hard-hit countries have “flattened the curve” and are easing lockdowns put in place to slow the spread of the novel virus while others, such as the cities of Barcelona and Melbourne, are implementing a second round of local shutdowns.

The number of cases globally is around triple that of severe influenza illnesses recorded annually, according to the World Health Organization.

The pandemic has now killed more than 590,000 people in almost seven months, edging towards the upper range of yearly influenza deaths reported worldwide. The first death was reported on Jan. 10 in Wuhan, China before infections and fatalities then surged in Europe and later in the United States.

The Reuters tally, which is based on government reports, shows the disease is accelerating the fastest in the Americas, which account for more than half the world’s infections and half its deaths.

In Brazil, more than 2 million people have tested positive including President Jair Bolsonaro, and more than 76,000 people have died.

India, the only other country with more than 1 million cases, has been grappling with an average of almost 30,000 new infections each day for the last week.

Those countries were the main drivers behind the World Health Organization on Friday reporting a record one-day increase in global coronavirus cases of 237,743.

In countries with limited testing capacity, case numbers reflect only a proportion of total infections. Experts say official data likely under-represents both infections and deaths. - Reuters

Flights increase gradually by August...!!!
https://www.businesstraveller.com/business-travel/2020/07/17/singapore-airlines-to-increase-flights-in-august/

Covid19 Vaccine in September.

British pharma giant AstraZeneca is "on track" to begin rolling out up to two billion doses of a coronavirus vaccine in September if ongoing trials prove successful, its chief executive said on Friday.

The company is partnering with Oxford University, which has pioneered the vaccine, and is already manufacturing doses before seeking final regulatory approval once testing concludes in the coming months.

"So far we're still on track... we are starting to manufacture this vaccine right now, and we have to have it ready to be used by the time we have the results," AstraZeneca chief executive Pascal Soriot told BBC radio.

"Our present assumption is that we will have the data by the end of the summer, by August, so in September we should know whether we have an effective vaccine or not."

The firm announced this week it had struck agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India to double production capacity of the COVID-19 vaccine to two billion doses.

The partnership with the Indian institute—one of the world's largest vaccine manufacturers—will help supply it to a large number of low- and middle-income countries.

AstraZeneca has established separate supply chains for the vaccine in Europe, the United States, India and is also looking at setting up production in China, Soriot said.

He added AstraZeneca, which is undertaking the work on a non-profit basis, could lose money if trials prove disappointing.

But he said the company was sharing the financial risk with organisations such as CEPI.

"We're manufacturing indeed at risk—and that's the only way to have the vaccine ready to go if it works," he added.

Oxford University began initial trials of its COVID-19 vaccine with hundreds of volunteers in April, and is now expanding them to 10,000 participants.

It said last month they were "progressing very well".

Researchers announced this week they will also start tests in mid-June in Brazil, the first country outside Britain to take part in the study, as the South American country's virus infection rate spirals while the UK's falls.

Chinese vaccine candidate effective against all known coronavirus strains: Sinopharm
By Fan Wei Source: Global Times Published: 2020/7/16 16:20:26
15
We are racing with the virus, not the US: Sinopharm president

A Chinese-developed inactivated COVID-19 vaccine candidate is effective against all detected strains of the virus so far, with lower chance and degree of adverse reactions than same-typed vaccine candidates under research, the head of the vaccine candidate's producer told the Global Times in an exclusive interview on Monday.

"The inactivated vaccine we developed can cover all strains of the coronavirus that have been detected so far, including the virus strains tracked in the Xinfadi market in Beijing," Yang Xiaoming, president of China National Pharmaceutical Group (Sinopharm), noted in response to public concerns that the vaccine under the R&D process would be ineffective as the virus mutates.

The research team has carried out cross-protection experiments to test if the anti-serum obtained by immunizing animals can produce an immune response to different genotypes of strains of coronavirus, Yang said.

Sinopharm, whose COVID-19 inactivated vaccine candidates have been delivered into phase three clinical trials, have stored more than 4 million doses of the vaccines, the Global Times learned from the group.

Yang said that the group is currently storing more COVID-19 vaccines. Once a candidate is approved for the market, the company will soon be able to provide as many doses of vaccines as the country needs.

Yang estimated that an inactivated COVID-19 vaccine will be available on the market at the end of this year or early 2021. Two inactivated COVID-19 vaccine candidates separately developed by Sinopharm institutes in Beijing and Wuhan entered clinical trials in April.

The results of phase one and two clinical trials of the two candidates were revealed in June, showing that all receptors have created high-titer antibodies.

Skepticism and pessimism of Chinese-developed COVID-19 vaccines have been raised in some Western media, which have exaggerated the side effect ratio reported in early-stage clinical trials of another vaccine candidate, the Ad5-nCoV recombinant novel coronavirus vaccine.

Vaccine experts advised the public not to panic over the side effects revealed in the preliminary results of the Chinese-developed coronavirus vaccine, as the adverse reactions exposed are tolerable and the vaccine is under constant optimization.

Yang also reveals that more than 1,000 Sinopharm group employees have been receiving injections on a voluntary basis, and the results show a promising trend that the vaccine is safe and effective, with low incidence and degree of adverse reactions.

At the end of May, 180 volunteers from Sinopharm received inactivated COVID-19 vaccinations, and their antibodies have reached levels resistant to the coronavirus with a 100 percent protective rate.

On June 23, Sinopharm signed agreements with the United Arab Emirates (UAE) government to conduct COVID-19 vaccine candidate phase three clinical trials in the country, the world's first COVID-19 vaccine candidate phase three clinical trials to have been launched.

China's National Medical Products Administration on Thursday stressed the need to promote the development and marketing of COVID-19 vaccines, and take the initiative to help pharmaceutical companies resume work and production.

As China and the US have been given great hopes on providing panacea for the coronavirus, their respective vaccine R&D pace has drawn much media attention. Some have called the vaccine development "a race between two countries currently caught in strained ties."

Leading US medical expert Anthony Fauci expressed his confidence in prospects for the US vaccine on Wednesday, and said he does not expect China to win the vaccine race, Reuters reported.

"The COVID war between the US and China is looking like a race to the moon. Being first to develop COVID treatments and vaccines has become a point of national pride," Lawrence Gostin, the director of Georgetown University's O'Neill Institute for National and Global Health Law, was quoted as saying in the report of Business Insider. "A 'my country first' attitude is highly counterproductive. We need to work cooperatively as a global and scientific community."

"We are racing with the coronavirus but not with the US [to be the first with successful vaccine]", Yang argued, claiming that all their efforts are part of China's commitment to make the vaccine available to the international community.

Yang said he hopes to see Chinese-developed vaccines against coronavirus accessible and affordable for developing countries when they turn out. He expects further global cooperation in COVID-19 vaccine trials to help stop the pandemic that has infected millions.

Chinese vaccine candidate effective against all known coronavirus strains: Sinopharm
By Fan Wei Source: Global Times Published: 2020/7/16 16:20:26
15
We are racing with the virus, not the US: Sinopharm president

A Chinese-developed inactivated COVID-19 vaccine candidate is effective against all detected strains of the virus so far, with lower chance and degree of adverse reactions than same-typed vaccine candidates under research, the head of the vaccine candidate's producer told the Global Times in an exclusive interview on Monday.

"The inactivated vaccine we developed can cover all strains of the coronavirus that have been detected so far, including the virus strains tracked in the Xinfadi market in Beijing," Yang Xiaoming, president of China National Pharmaceutical Group (Sinopharm), noted in response to public concerns that the vaccine under the R&D process would be ineffective as the virus mutates.

The research team has carried out cross-protection experiments to test if the anti-serum obtained by immunizing animals can produce an immune response to different genotypes of strains of coronavirus, Yang said.

Sinopharm, whose COVID-19 inactivated vaccine candidates have been delivered into phase three clinical trials, have stored more than 4 million doses of the vaccines, the Global Times learned from the group.

Yang said that the group is currently storing more COVID-19 vaccines. Once a candidate is approved for the market, the company will soon be able to provide as many doses of vaccines as the country needs.

Yang estimated that an inactivated COVID-19 vaccine will be available on the market at the end of this year or early 2021. Two inactivated COVID-19 vaccine candidates separately developed by Sinopharm institutes in Beijing and Wuhan entered clinical trials in April.

The results of phase one and two clinical trials of the two candidates were revealed in June, showing that all receptors have created high-titer antibodies.

Skepticism and pessimism of Chinese-developed COVID-19 vaccines have been raised in some Western media, which have exaggerated the side effect ratio reported in early-stage clinical trials of another vaccine candidate, the Ad5-nCoV recombinant novel coronavirus vaccine.

Vaccine experts advised the public not to panic over the side effects revealed in the preliminary results of the Chinese-developed coronavirus vaccine, as the adverse reactions exposed are tolerable and the vaccine is under constant optimization.

Yang also reveals that more than 1,000 Sinopharm group employees have been receiving injections on a voluntary basis, and the results show a promising trend that the vaccine is safe and effective, with low incidence and degree of adverse reactions.

At the end of May, 180 volunteers from Sinopharm received inactivated COVID-19 vaccinations, and their antibodies have reached levels resistant to the coronavirus with a 100 percent protective rate.

On June 23, Sinopharm signed agreements with the United Arab Emirates (UAE) government to conduct COVID-19 vaccine candidate phase three clinical trials in the country, the world's first COVID-19 vaccine candidate phase three clinical trials to have been launched.

China's National Medical Products Administration on Thursday stressed the need to promote the development and marketing of COVID-19 vaccines, and take the initiative to help pharmaceutical companies resume work and production.

As China and the US have been given great hopes on providing panacea for the coronavirus, their respective vaccine R&D pace has drawn much media attention. Some have called the vaccine development "a race between two countries currently caught in strained ties."

Leading US medical expert Anthony Fauci expressed his confidence in prospects for the US vaccine on Wednesday, and said he does not expect China to win the vaccine race, Reuters reported.

"The COVID war between the US and China is looking like a race to the moon. Being first to develop COVID treatments and vaccines has become a point of national pride," Lawrence Gostin, the director of Georgetown University's O'Neill Institute for National and Global Health Law, was quoted as saying in the report of Business Insider. "A 'my country first' attitude is highly counterproductive. We need to work cooperatively as a global and scientific community."

"We are racing with the coronavirus but not with the US [to be the first with successful vaccine]", Yang argued, claiming that all their efforts are part of China's commitment to make the vaccine available to the international community.

Yang said he hopes to see Chinese-developed vaccines against coronavirus accessible and affordable for developing countries when they turn out. He expects further global cooperation in COVID-19 vaccine trials to help stop the pandemic that has infected millions.

wehcant geary, friends think I was crazy to bet on Comfort early this year. I remember that time, most people were talking about where to buy face masks in bulk and resell for a premium. A friend even went to India to source for face masks.
17/07/2020 5:00 PM

Foresight...Caculated Risks...Patience...Boring Time...Success...◉‿◉

wehcant Who said you can't make your first million in stocks trading?
17/07/2020 4:49 PM

Power...◉‿◉

Mabel I'm still waiting for my 60 sen

Meow..
17/07/2020 3:56 PM

Me too...◉‿◉

xuxu geary next week will stand above 4.0 hehe
17/07/2020 4:50 PM

Yup...(◔‿◔)

@3.90...(◠‿◕)

xuxu yesterday added now good profit already hehe.

Baby Shark And now 36k..
17/07/2020 4:39 PM

@3.90...(◠‿◕)

Baby Shark 200,000 shares average 3.70.. now 30k
17/07/2020 4:32 PM

(◠‿◕)

Baby Shark Bought banyak dah.. now wait Rm6.00
17/07/2020 11:57 AM

｡◕‿◕｡

xuxu geary come back again tomorrow, thats all for today. tomorrow green2 hehe
16/07/2020 4:54 PM

(◠‿◕)

KUALA LUMPUR (July 16): Trading platforms have encountered a technical glitch in the afternoon trading session today.

It is rumoured that Bursa Malaysia's trading system has hung due to a massive turnover in trading orders.

At the time of writing, price quotes across online platforms have frozen. As at 3.30pm, trading volume was at 9.28 billion, while turnover stood at RM4.14 billion.

According to an SMS text message to clients from Kenanga Investment Bank, there is an industry-wide service disruption connecting to Bursa Malaysia since 3.30pm.

"Currently all orders have been rejected by Bursa Malaysia. Please be patient and we will update further on this," it said.

BabyAce I wonder what will glove holders do once trading resume? :) this is not the first time Bursa is so incompetent.
16/07/2020 4:27 PM

Singapore SGX also had such technical issue before...Rectified already under the new boss...Sack them...before foreign funds all run away...!!!

tahong Only glove counters need to be worry as other counters not move much
16/07/2020 4:17 PM

Buy on Weakness...Sell on strength...If not today trading volume should be above 12 billions...Halted...Bursa must upgrade their technical issue on this high trading activities...!!!

qwerting1 Bursa activated circuit breaker.. the trading will halt for the rest of session.Market will reopen tomorrow.
16/07/2020 3:47 PM

Nationwide all halted...By 3.30pm...trading was above 9 billions...System technical fault...!!!

Oh...!!!
https://kr-asia.com/airasia-ends-up-rehiring-its-laid-off-employees-to-work-for-its-agriculture-e-commerce-site

Frank Tan This Mama will have fews stage of earning for us:
1.it is now
2.when china/america announce another stage of vaccine success
3.started to manufacture the vaccine
4 started to distribute the vaccine
5.when QR shows good profit.
Sounds good or dreaming?
Moreover Dphama with good FA,good dividen history,epf keep buying...
U know wat to do now ya..cheers
16/07/2020 9:53 AM

Yup become Yuppie...!!!

Frank Tan @geary Good start today,both Ma Ma also

Both horses racing...for the 1st Price...hehehe...!!!

Upswinging...｡◕‿◕｡

Mabel So Nice and so Green...

Meow

https://www.cnbc.com/2020/07/15/airasia-is-confident-it-can-return-to-profitability-in-2021-ceo-says.html

KAQ4468 hahahaha

I sudah Whatsapp sama dia lah semalam...!!!


dia cakap lu orang kasi hantam dulu la .....dia pun tunggu 40 cents wooooooo




kah kah kah
15/07/2020 4:49 PM

Alamak...Bankrupt lah saya...!!!

KAQ4468 apa pasal dia sendiri tarak buy back lagi now at low as 70 cents ??????


tarak confident ka ???????
15/07/2020 4:27 PM

Whatsapp to him lah...!!!

xuxu uncle says don't sell means buy lah

Hahaha...!!!

geary Frank Tan come on,limit up again...

Yup... bought...@1.81...!!!

TG...@2.40...!!!

AirAsia confident of returning to the black by 2021, says Tony Fernandes | https://www.klsescreener.com/v2/news/view/702557

xuxu geary haha, nvm just buy and hold, thk you. you sold all already ?

Sold some on margin...Hold some till Jan 2021...!!!

xuxu aiyo, just bought then drop already haizzzzz

Crucially u hold this untrending card...Patience...some vaccine news disruptions...n profit taking...within few days only this sentiments...!!!

For now let’s loved Comfort

Until January 2021...｡◕‿◕｡

Frank Tan come on,limit up again...

Yup... bought...@1.81...!!!

dusti don’t worry about vaccine. If discovered in US will be too expensive. Anyway use of gloves has been incorporated in health SOP of many countries and will be in use forever. So..........

Ha...US 50...per shot of vaccine...yup gloves will be used in most places...SOP...◉‿◉

stockraider MOST IMPORTANTLY I TRY TO HEDGE MY BETS WITH DPHARMA LOH...!

ACTION:
i. try to hold TIGHT
ii. try add at low pts
3. TRY TO HEDGE BETS WITH DPHARMA MAH..!

Power..^^^!!!

Jiasaihooi Wah, Mega sales. promotion, Buy buy Buy!

Supporting...@3.70-3.80...!!!

uniteen early in the morning got interesting story from mabel already. lol

EQ. ..lady knows better...***

sampooler "Tata Sons plans to quit AirAsia India venture"

Old news is no news...today new beginning...:-)

Uptrending...:-)
https://theconversation.com/mask-resistance-during-a-pandemic-isnt-new-in-1918-many-americans-were-slackers-141687

MAHB: Air travel in Malaysia showing further signs of recovery in the first nine days of July 2020 | https://www.klsescreener.com/v2/news/view/702267

Slightly Up...:-)

Uptrending...:-)
https://finance.yahoo.com/news/stock-market-news-live-july-14-2020-221802899.html

Upswing...breakout above...@4.37...(θ‿θ)

Up slightly again...◉‿◉

Upswinging slightly...ʘ‿ʘ